Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites.

[1]  M. Rogers,et al.  Spironolactone Metabolism: Steady‐State Serum Levels of the Sulfur‐Containing Metabolites , 1989, Journal of clinical pharmacology.

[2]  F. Merkus,et al.  New insights into the pharmacokinetics of spironolactone , 1985, Clinical pharmacology and therapeutics.

[3]  K. Yamamoto,et al.  Pharmacokinetics of spironolactone and potassium canrenoate in humans. , 1985, Journal of pharmacobio-dynamics.

[4]  Brater Dc.  Determinants of the overall response to furosemide: pharmacokinetics and pharmacodynamics. , 1983 .

[5]  R. Perkins,et al.  Spironolactone dose-response relationships in healthy subjects. , 1982, British journal of clinical pharmacology.

[6]  G. Mcinnes,et al.  Dose‐response relationships for spironolactone at steady state , 1982, Clinical pharmacology and therapeutics.

[7]  G. Mcinnes,et al.  Activity of sulfur‐containing intermediate metabolites of spironolactone , 1980, Clinical pharmacology and therapeutics.

[8]  W. Bartle,et al.  Effect of neomycin on the bioavailability of spironolactone: a single-dose study. , 1979, American journal of hospital pharmacy.

[9]  J. Shelton,et al.  Spironolactone and potassium canrenoate in normal man , 1976, Clinical pharmacology and therapeutics.

[10]  A. Karim,et al.  Spironolactone. I. Disposition and metabolism , 1976, Clinical pharmacology and therapeutics.

[11]  T. Hutsell,et al.  Spironolactone. III. Canrenone—maximum and minimum steady‐state plasma levels , 1976, Clinical pharmacology and therapeutics.

[12]  T. Hutsell,et al.  Spironolactone. II. Bioavailability , 1976, Clinical pharmacology and therapeutics.

[13]  D. Feldman,et al.  Molecular modifications of anti-aldosterone compounds: effects on affinity of spirolactones for renal aldosterone receptors. , 1974, Biochemical pharmacology.

[14]  A. Karim,et al.  Isolation and identification of novel sulfur-containing metabolites of spironolactone (Aldactone). , 1972, Steroids.

[15]  Malcolm Rowland,et al.  Clinical pharmacokinetics : concepts and applications , 1989 .

[16]  J. Zuidema,et al.  Pharmacokinetics of spironolactone after a single dose: evaluation of the true canrenone serum concentrations during 24 hours. , 1983, Clinical and Experimental Hypertension Part A Theory and Practice.

[17]  A. Karim,et al.  Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability. , 1978, Drug metabolism reviews.

[18]  A. Váradi,et al.  Spironolactone metabolism in normal subjects and in patients with liver cirrhosis. , 1977, Arzneimittel-Forschung.